Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00568451 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00568451: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT00568451 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00568451, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving paclitaxel together with carboplatin is more effective than giving temozolomide alone in treating patients with melanoma. PURPOSE: This phase II trial is studying the side effects and how well giving paclitaxel together with carboplatin or giving temozolomide alone works in treating patients with stage IV melanoma.
Interventions
- DRUG carboplatin
- DRUG temozolomide
- DRUG paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2006-06 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00568451
The ClinicalTrials.gov registry entry for NCT00568451 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which carboplatin is the first listed.
NCT00568451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00568451 about?
NCT00568451 is a clinical study titled "Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma". RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving paclitaxel together with carboplatin is more effective than giving temozolomide alone in treating patients...
What is the current status of trial NCT00568451?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2006-06. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00568451?
The interventions under investigation include: carboplatin (DRUG), temozolomide (DRUG), paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00568451?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.